Final results of the MIN-001-1203 study with 2OHOA in oncology presented at ASCO 2017 annual meeting in Chicago

54 patients with advanced solid tumours have participated in the Phase I/IIa clinical study with 2OHOA, half of them with malignant glioma. Primary objective has been achieved, with the definition or the MTD, the confirmation of an excellent safety profile, even at doses well above the expected therapeutic range and the identification of the recommended Phase 2 dose (RP2D). A favourable PK profile, with no food‑effect interactions and supporting oral dosing of 2OHOA was also determined. Very encouraging clinical activity has been observed in at least 8 patients with recurrent solid tumours, five of them with malignant glioma. Preliminary biomarkers analysis confirm biological activity of 2OHOA in patients and several potential plasmatic biomarkers have already been identified for future development and validation.

Palma de Mallorca, June 5^th 2017. – Lipopharma, a pioneering clinical stage biopharmaceutical company developing a new generation of products modulating metabolism of membrane lipids based on the groundbreaking MLT platform, announced today that the final results of the of MIN-001-1203 clinical study with 2OHOA in patients with advanced solid tumours, including malignant glioma, have been presented at a poster session within the Developmental Therapeutics and Translational Research track at the 2017 ASCO meeting in Chicago. 5 leading clinical investigational sites in Spain and in the UK have participated in this study

Read more: Final results of the MIN-001-1203 study with 2OHOA in oncology presented at ASCO 2017 annual...